Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
The current price of 3IP.F is €33 EUR — it has increased by +0.61% in the past 24 hours. Watch Harrow stock price performance more closely on the chart.
What is Harrow stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Harrow stocks are traded under the ticker 3IP.F.
When is the next Harrow earnings date?▼
Harrow is going to release the next earnings report on May 11, 2026.
What were Harrow earnings last quarter?▼
3IP.F earnings for the last quarter are 0.15 EUR per share, whereas the estimation was 0.31 EUR resulting in a -53.78% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Harrow have?▼
As of May 06, 2026, the company has 125 employees.